Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 883

1.

Features of and preventive measures against hypertension in the young.

Kawabe H, Azegami T, Takeda A, Kanda T, Saito I, Saruta T, Hirose H.

Hypertens Res. 2019 Jul;42(7):935-948. doi: 10.1038/s41440-019-0229-3. Epub 2019 Mar 20. Review.

PMID:
30894695
2.

Effects of Calcium-Channel Blocker Benidipine-Based Combination Therapy on Cardiac Events - Subanalysis of the COPE Trial.

Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Shimada K, Kawana M, Kario K, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial Group.

Circ J. 2018 Jan 25;82(2):457-463. doi: 10.1253/circj.CJ-17-0592. Epub 2017 Sep 2.

3.

On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension.

Yano Y, Rakugi H, Bakris GL, Lloyd-Jones DM, Oparil S, Saruta T, Shimada K, Matsuoka H, Imai Y, Ogihara T.

Hypertension. 2017 Feb;69(2):220-227. doi: 10.1161/HYPERTENSIONAHA.116.08600. Epub 2017 Jan 3.

PMID:
28049699
4.

Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial.

Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial Group.

Hypertens Res. 2017 Apr;40(4):376-384. doi: 10.1038/hr.2016.158. Epub 2016 Dec 1.

5.

Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability: post hoc analysis of the COPE trial.

Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events COPE Trial Group.

Hypertens Res. 2016 Jan;39(1):46-53. doi: 10.1038/hr.2015.104. Epub 2015 Oct 22.

6.

Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis.

Rakugi H, Ogihara T, Saruta T, Kawai T, Saito I, Teramukai S, Shimada K, Katayama S, Higaki J, Odawara M, Tanahashi N, Kimura G; COLM Investigators.

J Hypertens. 2015 Oct;33(10):2165-72. doi: 10.1097/HJH.0000000000000668.

7.

Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial.

Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Teramukai S, Higaki J, Ito S, Shimada K; COLM Investigators.

Hypertens Res. 2015 Jan;38(1):89-96. doi: 10.1038/hr.2014.144. Epub 2014 Sep 25.

8.

Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability.

Saruta T, Ogihara T, Saito I, Rakugi H, Shimamoto K, Matsuoka H, Teramukai S, Higaki J, Ito S, Shimada K.

Hypertens Res. 2015 Feb;38(2):132-6. doi: 10.1038/hr.2014.141. Epub 2014 Sep 25.

9.

A randomised controlled trial for the evaluation of risk for type 2 diabetes in hypertensive patients receiving thiazide diuretics: Diuretics In the Management of Essential hypertension (DIME) study.

Ueda S, Morimoto T, Ando S, Takishita S, Kawano Y, Shimamoto K, Ogihara T, Saruta T; DIME Investigators.

BMJ Open. 2014 Jul 16;4(7):e004576. doi: 10.1136/bmjopen-2013-004576.

10.

Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.

Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Shimada K, Ito S, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Kimura G, Umemura S, Ura N, Hayashi K, Odawara M, Tanahashi N, Ishimitsu T, Kashihara N, Morita S, Teramukai S; COLM Investigators.

J Hypertens. 2014 Oct;32(10):2054-63; discussiom 2063. doi: 10.1097/HJH.0000000000000281.

11.

[Influence of physicians' subspecialty and training history on CKD management and medical cooperation: from the results of a nationwide questionnaire survey for primary care physicians].

Naito T, Ohtani H, Kobayashi K, Miyazaki M, Yamada K, Sugawara M, Naka Y, Saruta T.

Nihon Jinzo Gakkai Shi. 2013;55(8):1401-11. Japanese.

PMID:
24568037
12.

[Current status of and regional differences in CKD management and medical cooperation in Japan: from the results of a nationwide questionnaire survey for primary care physicians].

Naito T, Ohtani H, Kobayashi K, Miyazaki M, Yamada K, Sugawara M, Naka Y, Saruta T.

Nihon Jinzo Gakkai Shi. 2013;55(8):1391-400. Japanese.

PMID:
24568036
13.

Rho-kinase contributes to pressure-induced constriction of renal microvessels.

Homma K, Hayashi K, Wakino S, Tokuyama H, Kanda T, Tatematsu S, Hasegawa K, Fujishima S, Hori S, Saruta T, Itoh H.

Keio J Med. 2014;63(1):1-12. Epub 2014 Jan 16.

14.

Renal thrombotic microangiopathy in a patient with septic disseminated intravascular coagulation.

Sakamaki Y, Konishi K, Hayashi K, Hashiguchi A, Hayashi M, Kubota E, Saruta T, Itoh H.

BMC Nephrol. 2013 Nov 27;14:260. doi: 10.1186/1471-2369-14-260.

15.
16.

Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: the COPE trial.

Umemoto S, Ogihara T, Rakugi H, Matsumoto M, Kitagawa K, Shimada K, Higaki J, Ito S, Suzuki H, Ohashi Y, Saruta T, Matsuzaki M; Combination Therapy of Hypertension to Prevent Cardiovascular.

Hypertens Res. 2013 Dec;36(12):1088-95. doi: 10.1038/hr.2013.100. Epub 2013 Aug 29.

PMID:
23985703
17.

Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial.

Rakugi H, Ogihara T, Umemoto S, Matsuzaki M, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group.

Hypertens Res. 2013 Nov;36(11):947-58. doi: 10.1038/hr.2013.63. Epub 2013 Jul 18.

PMID:
23864054
18.

Anti-allergic effects of Vernonia amygdalina leaf extracts in hapten-induced atopic dermatitis-like disease in mice.

Ngatu NR, Okajima MK, Yokogawa M, Hirota R, Takaishi M, Eitoku M, Muzembo BA, Sabah AB, Saruta T, Miyamura M, Kaneko T, Sano S, Suganuma N.

Allergol Int. 2012 Dec;61(4):597-607. doi: 10.2332/allergolint.11-OA-0393. Epub 2012 Aug 25.

19.

Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial.

Ogihara T, Matsuzaki M, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group.

Hypertens Res. 2012 Apr;35(4):441-8. doi: 10.1038/hr.2011.216. Epub 2012 Jan 26.

PMID:
22278623
20.

Brazilian green propolis extracts improve Tinea pedis interdigitalis and Tinea corporis.

Ngatu NR, Saruta T, Hirota R, Eitoku M, Luzitu NS, Muzembo BA, Matsui T, Suganuma N.

J Altern Complement Med. 2012 Jan;18(1):8-9. doi: 10.1089/acm.2011.0696. Epub 2012 Jan 9. No abstract available.

PMID:
22229708
21.

Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure.

Kumagai H, Oshima N, Matsuura T, Iigaya K, Imai M, Onimaru H, Sakata K, Osaka M, Onami T, Takimoto C, Kamayachi T, Itoh H, Saruta T.

Hypertens Res. 2012 Feb;35(2):132-41. doi: 10.1038/hr.2011.208. Epub 2011 Dec 15.

22.

Baro-excited neurons in the caudal ventrolateral medulla (CVLM) recorded using the whole-cell patch-clamp technique.

Oshima N, Kumagai H, Iigaya K, Onimaru H, Kawai A, Nishida Y, Saruta T, Itoh H.

Hypertens Res. 2012 May;35(5):500-6. doi: 10.1038/hr.2011.211. Epub 2011 Dec 8.

PMID:
22158117
23.

Optimal Combination of Effective ANtihypertensives (OCEAN) study: a prospective, randomized, open-label, blinded endpoint trial--rationale, design and results of a pilot study in Japan.

Kageyama S, Ueda S, Mochizuki K, Miyakawa M, Sugawara M, Nakayama M, Ohashi Y, Saito I, Saruta T; OCEAN Study Group.

Hypertens Res. 2012 Feb;35(2):221-7. doi: 10.1038/hr.2011.178. Epub 2011 Nov 17.

PMID:
22089534
24.

Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).

Ogihara T, Ueshima K, Nakao K, Fukiyama K, Oba K, Yasuno S, Fujimoto A, Sato T, Matsuoka H, Saruta T; CASE-J Ex Study Group.

Hypertens Res. 2011 Dec;34(12):1295-301. doi: 10.1038/hr.2011.120. Epub 2011 Aug 11.

PMID:
21833000
25.

Association of blood pressure control and metabolic syndrome with cardiovascular risk in elderly Japanese: JATOS study.

Kawano Y, Ogihara T, Saruta T, Goto Y, Ishii M.

Am J Hypertens. 2011 Nov;24(11):1250-6. doi: 10.1038/ajh.2011.138. Epub 2011 Aug 4.

PMID:
21814293
26.

Treatment of hypertension in patients 85 years of age or older: a J-BRAVE substudy.

Saito I, Suzuki H, Kageyama S, Saruta T.

Clin Exp Hypertens. 2011;33(5):275-80. doi: 10.3109/10641963.2011.577483.

PMID:
21787236
28.

How to use marginal structural models in randomized trials to estimate the natural direct and indirect effects of therapies mediated by causal intermediates.

Oba K, Sato T, Ogihara T, Saruta T, Nakao K.

Clin Trials. 2011 Jun;8(3):277-87. doi: 10.1177/1740774511402526. Erratum in: Clin Trials. 2011;8(5):680.

29.

Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.

Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group.

J Hypertens. 2011 Aug;29(8):1649-59. doi: 10.1097/HJH.0b013e328348345d.

PMID:
21610513
30.

[The process leading up to publication of the 100th volume of the Journal of the Japanese Society of Internal Medicine. Discussion].

Asaka M, Saruta T, Saito H, Kanou S, Kudo S, Kuramoto T.

Nihon Naika Gakkai Zasshi. 2011 Jan 10;100(1):2-19. Japanese. No abstract available.

PMID:
21500614
31.

Coactivation of SF-1-mediated transcription of steroidogenic enzymes by Ubc9 and PIAS1.

Suda N, Shibata H, Kurihara I, Ikeda Y, Kobayashi S, Yokota K, Murai-Takeda A, Nakagawa K, Oya M, Murai M, Rainey WE, Saruta T, Itoh H.

Endocrinology. 2011 Jun;152(6):2266-77. doi: 10.1210/en.2010-1232. Epub 2011 Apr 5.

32.

Effect of antihypertensive treatment on cardiovascular events in elderly hypertensive patients: Japan's Benidipine Research on Antihypertensive Effects in the Elderly (J-BRAVE).

Saito I, Suzuki H, Kageyama S, Saruta T.

Clin Exp Hypertens. 2011;33(2):133-40. doi: 10.3109/10641963.2010.546467. Epub 2011 Jan 26.

PMID:
21269056
33.

Age-related differences in the effects of antihypertensive therapy on left ventricular hypertrophy in high-risk patients with hypertension-candesartan antihypertensive survival evaluation in Japan subanalysis.

Ogihara T, Fujimoto A, Ueshima K, Nakao K, Saruta T.

J Am Geriatr Soc. 2011 Jan;59(1):180-1. doi: 10.1111/j.1532-5415.2010.03215.x. No abstract available.

PMID:
21226700
34.

[Aldosterone].

Saruta T.

Nihon Rinsho. 2010 Jul;68 Suppl 7:354-7. Japanese. No abstract available.

PMID:
20963881
35.

T-type Ca channel blockade as a determinant of kidney protection.

Hayashi K, Homma K, Wakino S, Tokuyama H, Sugano N, Saruta T, Itoh H.

Keio J Med. 2010;59(3):84-95. Review.

36.

Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine.

Hayashi K, Saruta T, Goto Y, Ishii M; JATOS Study Group.

Hypertens Res. 2010 Nov;33(11):1211-20. doi: 10.1038/hr.2010.162. Epub 2010 Sep 16.

PMID:
20844543
37.

Impact of left ventricular hypertrophy on the time-course of renal function in hypertensive patients – a subanalysis of the CASE-J trial –.

Ueshima K, Yasuno S, Oba K, Fujimoto A, Mukoyama M, Ogihara T, Saruta T, Nakao K.

Circ J. 2010 Oct;74(10):2132-8. Epub 2010 Aug 21.

38.
39.

Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study.

Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H; Valsartan in Elderly Isolated Systolic Hypertension Study Group.

Hypertension. 2010 Aug;56(2):196-202. doi: 10.1161/HYPERTENSIONAHA.109.146035. Epub 2010 Jun 7.

PMID:
20530299
40.

Absence of gelatinase (MMP-9) or collagenase (MMP-13) attenuates adriamycin-induced albuminuria and glomerulosclerosis.

Sakamaki Y, Sasamura H, Hayashi K, Ishiguro K, Takaishi H, Okada Y, D'Armiento JM, Saruta T, Itoh H.

Nephron Exp Nephrol. 2010;115(2):e22-32. doi: 10.1159/000312883. Epub 2010 Apr 21.

PMID:
20407279
41.

Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.

Nakao K, Hirata M, Oba K, Yasuno S, Ueshima K, Fujimoto A, Ogihara T, Saruta T; CASE-J Trial Group.

Hypertens Res. 2010 Jun;33(6):600-6. doi: 10.1038/hr.2010.38. Epub 2010 Apr 9.

PMID:
20379187
42.

Effects of antihypertensive drugs in the prevention of new-onset diabetes mellitus in patients with hypertension at high-risk of cardiovascular events in relation to aging.

Ogihara T, Fujimoto A, Nakao K, Saruta T.

J Am Geriatr Soc. 2010 Feb;58(2):395-6. doi: 10.1111/j.1532-5415.2009.02696.x. No abstract available.

PMID:
20370872
43.

Association of increased reactive oxygen species production with abdominal obesity in type 2 diabetes.

Hirao K, Maruyama T, Ohno Y, Hirose H, Shimada A, Takei I, Murata M, Morii T, Eguchi T, Hayashi M, Saruta T, Itoh H.

Obes Res Clin Pract. 2010 Apr-Jun;4(2):e83-e162. doi: 10.1016/j.orcp.2009.09.004.

PMID:
24345646
44.

Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients?: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.

Yasuno S, Ueshima K, Oba K, Fujimoto A, Hirata M, Ogihara T, Saruta T, Nakao K.

Diabetes Care. 2010 May;33(5):1122-7. doi: 10.2337/dc09-1447. Epub 2010 Feb 25.

45.

NF-YC functions as a corepressor of agonist-bound mineralocorticoid receptor.

Murai-Takeda A, Shibata H, Kurihara I, Kobayashi S, Yokota K, Suda N, Mitsuishi Y, Jo R, Kitagawa H, Kato S, Saruta T, Itoh H.

J Biol Chem. 2010 Mar 12;285(11):8084-93. doi: 10.1074/jbc.M109.053371. Epub 2010 Jan 6.

47.

Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.

Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, Hirata T, Saruta T, Shimada A, Itoh H.

J Diabetes Complications. 2010 Nov-Dec;24(6):424-32. doi: 10.1016/j.jdiacomp.2008.10.005. Epub 2009 Aug 27.

PMID:
19716319
48.

Possible association of tumor necrosis factor receptor 2 gene polymorphism with severe hypertension using the extreme discordant phenotype design.

Eguchi T, Maruyama T, Ohno Y, Morii T, Hirao K, Hirose H, Kawabe H, Saito I, Hayashi M, Saruta T.

Hypertens Res. 2009 Sep;32(9):775-9. doi: 10.1038/hr.2009.91. Epub 2009 Jun 26.

PMID:
19557004
49.

Prevention and regression of hypertension: role of renal microvascular protection.

Sasamura H, Hayashi K, Ishiguro K, Nakaya H, Saruta T, Itoh H.

Hypertens Res. 2009 Aug;32(8):658-64. doi: 10.1038/hr.2009.85. Epub 2009 Jun 12. Review.

PMID:
19521419
50.

CD36 single nucleotide polymorphism is associated with variation in low-density lipoprotein-cholesterol in young Japanese men.

Morii T, Ohno Y, Kato N, Hirose H, Kawabe H, Hirao K, Eguchi T, Maruyama T, Hayashi M, Saito I, Yazaki Y, Saruta T.

Biomarkers. 2009 Jun;14(4):207-12. doi: 10.1080/13547500902811274.

PMID:
19489681

Supplemental Content

Loading ...
Support Center